◆英語タイトル:Omega Pharma NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012279
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company’s product portfolio includes cough and cold products, skin care products, pain relief products, vitamins, minerals, and nutritional supplements. Its products cater to gastro-intestinal disorders, respiratory issues, eye care, weight management, food supplements, baby care, and skin care. Besides, the company offers auto-diagnostic products such as body temperature meters, ovulation meters and blood pressure meters. It distributes these products to customers through retail distribution and drug store chains. Omega Pharma is headquartered in Nazareth, Belgium.
Omega Pharma NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Omega Pharma NV, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 13
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 14
Partnerships 16
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 16
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 17
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 18
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 19
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 20
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 21
Licensing Agreements 22
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 22
Equity Offering 23
Omega Pharma Completes Public Offering Of Shares For US$237 Million 23
Debt Offering 24
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 24
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 25
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 26
Acquisition 27
Perrigo Acquires Omega Pharma for USD4.76 Billion 27
Omega Pharma Acquires Naturoteek 29
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 30
Omega Pharma NV – Key Competitors 32
Omega Pharma NV – Key Employees 33
Omega Pharma NV – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Joint Venture 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Omega Pharma NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Omega Pharma NV, Deals By Therapy Area, 2011 to YTD 2017 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 13
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 14
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 16
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 17
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 18
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 19
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 20
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 21
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 22
Omega Pharma Completes Public Offering Of Shares For US$237 Million 23
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 24
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 25
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 26
Perrigo Acquires Omega Pharma for USD4.76 Billion 27
Omega Pharma Acquires Naturoteek 29
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 30
Omega Pharma NV, Key Competitors 32
Omega Pharma NV, Key Employees 33
Omega Pharma NV, Subsidiaries 34
Omega Pharma NV, Joint Venture 35